Skip to main content
    B

    BridgeBio Pharma Inc (BBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $77.36
    -0.94 (-1.20%)

    Market Cap: $15.25B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BridgeBio Pharma Inc (BBIO) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect BridgeBio Pharma (BBIO) to earn -$2.49 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.10B. Of 22 analysts, 19 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 1.91, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.

    RatingAnalystsShare
    Strong Buy522.7%
    Buy1463.6%
    Hold313.6%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    22

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 50.9%.

    Fiscal year ending Dec 31, 2026
    -$2.49
    EPS consensus, revenue $1.10B
    Fiscal year ending Dec 31, 2027
    -$0.27
    EPS consensus, revenue $1.66B

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.49-$2.81 to -$2.097$1.10B$1.07B to $1.12B16
    Dec 31, 2027-$0.27-$1.91 to $1.317$1.66B$1.48B to $1.88B18

    Quarterly Estimates

    The EPS consensus rises from -$0.62 for the quarter ending Dec 31, 2026 to -$0.37 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.62-$0.85 to -$0.1722$306.94M$267.83M to $334.57M20
    Mar 31, 2027-$0.37-$0.62 to -$0.154$338.05M$323.00M to $350.80M9

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202640
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.19.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.49-$2.62-$2.58-$2.58-$2.19N/A
    Fiscal year ending Dec 31, 2027-$0.27-$0.22$0.03$0.03$0.58N/A
    Quarter ending Mar 31, 2027-$0.37-$0.34-$0.36-$0.36-$0.11N/A

    Frequently Asked Questions About BBIO

    What is the BBIO stock forecast?

    Consensus analyst estimates put BridgeBio Pharma's EPS at -$2.49 for the fiscal year ending Dec 31, 2026, on revenue of $1.10B. The consensus rating from 22 analysts is Buy.

    How do analysts rate BBIO stock?

    Of 22 analysts covering BridgeBio Pharma, 5 rate it Strong Buy, 14 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from BBIO next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.49, with estimates from -$2.81 to -$2.09 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.27, with estimates from -$1.91 to $1.31 from 7 analysts.

    What revenue do analysts expect from BridgeBio Pharma next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.10B, with estimates from $1.07B to $1.12B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.66B, with estimates from $1.48B to $1.88B.

    How many analysts cover BBIO?

    22 analysts rate BridgeBio Pharma stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.